Newsroom

Press releases, peer-reviewed publications and conference presentations from BrainStorm Cell Therapeutics.

Get press releases by email

404 items

Latest from BrainStorm

Press release

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial r

Read the release

BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.